Methodology of clinical trials in COPD exacerbations: Eligibility criteria and endpoint selection.

A. Mathioudakis (Manchester, United Kingdom), M. Moberg (Hvidovre, Denmark), J. Janner (Hvidovre, Denmark), P. Alonso-Coello (Barcelona, Spain), J. Vestbo (Manchester, United Kingdom)

Source: International Congress 2018 – Innovative therapies in asthma and COPD
Session: Innovative therapies in asthma and COPD
Session type: Poster Discussion
Number: 609
Disease area: Airway diseases

Congress or journal article abstractSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Mathioudakis (Manchester, United Kingdom), M. Moberg (Hvidovre, Denmark), J. Janner (Hvidovre, Denmark), P. Alonso-Coello (Barcelona, Spain), J. Vestbo (Manchester, United Kingdom). Methodology of clinical trials in COPD exacerbations: Eligibility criteria and endpoint selection.. 609

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A systematic evaluation of the diagnostic criteria for COPD and exacerbations used in randomised controlled trials on the management of COPD exacerbations
Source: ERJ Open Res, 5 (4) 00136-2019; 10.1183/23120541.00136-2019
Year: 2019



Discordant diagnostic criteria for pneumonia in COPD trials: a review
Source: Eur Respir Rev, 30 (162) 210124; 10.1183/16000617.0124-2021
Year: 2021



Introduction: Evaluation criteria in clinical trials involving patients suffering from COPD
Source: Annual Congress 2003 - Progress on therapy for chronic obstructive pulmonary disease
Year: 2003

Limitations for the inclusion of patients in the Roflu-2011 study
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013


Classifying patients as GOLD A–D using the 2017 strategy criteria: impact on efficacy by GOLD stage in the OTEMTO tiotropium+olodaterol clinical trials
Source: International Congress 2017 – What is new in COPD diagnosis and classification?
Year: 2017


Dissociation between clinical trial inclusion and exclusion criteria for trials in severe asthma and the reality of the patient population
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014

COPD therapy based on clinical phenotypes: Baseline data from the Czech multicentre research database of COPD
Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD
Year: 2015


COPD severity analysis according to current evaluation criteria – National survey
Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD
Year: 2015


Persistence of clinical criteria of chronic bronchitis in patients with COPD over time: A longitudinal analysis of the TRACE cohort.
Source: International Congress 2017 – Markers of COPD progression
Year: 2017


Roflumilast for stable COPD: Meta-analysis of randomized controlled trials
Source: International Congress 2014 – Clinical presentations
Year: 2014


Simplification of the IDSA/ATS criteria for severe CAP using meta-analysis and observational data
Source: Eur Respir J 2014; 43: 842-851
Year: 2014




AUDIPOC: Spanish national clinical audit on COPD exacerbations. Results from the initial selection of cases
Source: Annual Congress 2009 - Epidemiology of COPD and infectious lung diseases
Year: 2009


Outcomes reported on the management of COPD exacerbations: a systematic survey of randomised controlled trials
Source: ERJ Open Res, 5 (2) 00072-2019; 10.1183/23120541.00072-2019
Year: 2019



Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013

Recommendations of the ATS/ERS Task Force for the definition of outcomes for COPD pharmacological trials
Source: Annual Congress 2006 - Outcomes for COPD pharmacological trials: from lung function to biomarkers
Year: 2006


Treatment eligibility of mepolizumab-treated severe asthma patients in clinical practice
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019

Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPD
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015


Eligibility of patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy
Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Year: 2015


The Spanish national clinical audit on COPD exacerbations (eCOPD). Pilot study: selection of study subjects
Source: Annual Congress 2008 - COPD in the elderly - quality of life and scores in COPD
Year: 2008